Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) sold by Tidal Investments LLC

Tidal Investments LLC reduced its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 31.6% in the first quarter, according to the company in its most recent SEC disclosure. The firm owned 7,724 shares of the biopharmaceutical company’s stock after selling 3,574 shares during the quarter. Tidal Investments LLC’s holdings in Halozyme Therapeutics were worth $314,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have recently bought and sold shares of the company. Rise Advisors LLC purchased a new stake in Halozyme Therapeutics in the 1st quarter valued at $25,000. Whittier Trust Co. purchased a new position in shares of Halozyme Therapeutics in the first quarter worth $27,000. Principal Securities Inc. purchased a new position in shares of Halozyme Therapeutics in the 4th quarter worth $34,000. Fidelis Capital Partners LLC purchased a new position in shares of Halozyme Therapeutics in the first quarter worth $52,000. Finally, First Horizon Advisors Inc. raised its stake in shares of Halozyme Therapeutics by 24.5% during the 4th quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 293 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s shares.

The Wall Street analyst weighs in

Several research analysts have recently issued reports on the company. Benchmark reaffirmed a “buy” rating and set a $60.00 target price on shares of Halozyme Therapeutics in a research note on Thursday. Goldman Sachs Group lifted their price target on Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a research note on Monday, July 22nd. Piper Sandler downgraded Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the stock from $48.00 to $51.00 in a research note on Friday, June 7th . JPMorgan Chase & Co. cut their price target on Halozyme Therapeutics from $53.00 to $52.00 and set an “overweight” rating for the company in a research note on Tuesday. Finally, JMP Securities decreased their price objective on Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating for the company in a research report on Wednesday. May 8. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company presently has an average rating of “Moderate Buy” and a consensus price target of $59.44, based on data from MarketBeat.com.

Read our latest research report on halozyme therapy

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Thursday, June 27th. The stock was sold at an average price of $51.93, for a total value of $519,300.00. Following the completion of the sale, the chief financial officer now owns 15,480 shares in the company, valued at approximately $803,876.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed via this link. Insiders have sold 45,000 shares of company stock worth $2,294,050 over the last 90 days. 2.40% of shares are owned by company insiders.

Halozyme Therapeutics trading up 1.4%

HALO traded up $0.74 during midday trading on Friday, hitting $55.20. The company’s stock had a trading volume of 827,455 shares, compared to its average volume of 1,252,118. The company has a current ratio of 6.64, a quick ratio of 5.36, and a debt-to-equity ratio of 8.44. The firm has a market cap of $7.03 billion, a P/E ratio of 22.81, a PEG ratio of 0.56 and a beta of 1.27. The firm has a 50 day moving average price of $52.29 and a two hundred day moving average price of $44.04. Halozyme Therapeutics, Inc. it has a 52-week low of $32.83 and a 52-week high of $57.08.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report ) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.73 by $0.18. The company had revenue of $231.40 million during the quarter, compared to analysts’ expectations of $204.94 million. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. The company’s revenue increased by 4.7% year-on-year. In the same quarter last year, the business earned $0.68 EPS. On average, research analysts anticipate that Halozyme Therapeutics, Inc. will post 3.66 earnings per share for the current year.

About Halozyme Therapeutics

(Free Report)

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the delivery of injectable biologics such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Featured stories

Want to see what other hedge funds own HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report).

Get Halozyme Therapeutics news and reviews daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Halozyme Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.